You are here

hemophilia A

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

Fierce Biotech

valoctocogene roxaparvovec

Flag link:

Bayer recalls mislabeled vials of hemophilia A treatment

Bayer recalls mislabeled vials of hemophilia A treatment

Fierce Pharma

product recalls

Flag link:

Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

Endpoints

Flag link:

Sangamo backs up early success for hemophilia gene therapy

Sangamo backs up early success for hemophilia gene therapy

Biopharma Dive

Spark Therapeutics

Flag link:

How BioMarin May Revolutionize the Hemophilia Treatment Market

How BioMarin May Revolutionize the Hemophilia Treatment Market

Motley Fool

Flag link:

Does Sangamo Have the Best Gene Therapy Program Now?

Does Sangamo Have the Best Gene Therapy Program Now?

Motley Fool

Sangamo Therapeutics

Flag link:

FDA Approves Roche Drug For All Hemophilia A Patients, But Rivals Loom

FDA Approves Roche Drug For All Hemophilia A Patients, But Rivals Loom

Xconomy

Flag link:

Roche reveals haemophilia drug data ahead of label expansion decision

Roche reveals haemophilia drug data ahead of label expansion decision

Pharmaforum

Flag link:

Bayer Secures FDA Approval for Hemophilia A Treatment, Jivi

Bayer Secures FDA Approval for Hemophilia A Treatment, Jivi

BioSpace

Flag link:

Spark’s gene therapy data answer some burning questions — and raise a few more

Spark’s gene therapy data answer some burning questions — and raise a few more

Stat

Spark Therapeutcs

Flag link:

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Endpoints

Flag link:

Roche drug dramatically reduces bleeds in key hemophilia tests

Roche drug dramatically reduces bleeds in key hemophilia tests

Reuters

clinical trials

Flag link:

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

BioPharma Dive

Spark Therapeutics

Flag link:

ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

BioPharma Dive

Flag link:

FDA Approves Genentech Hemophilia Drug, But Adds Safety Warning

FDA Approves Genentech Hemophilia Drug, But Adds Safety Warning

Xconomy

Flag link:

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

Endpoints

Flag link:

Bayer files longer-acting bleeding candidate to FDA

Bayer files longer-acting bleeding candidate to FDA

Fierce Biotech

Flag link:

Bioverativ taps patient social network for input on hemophilia trial design

Bioverativ taps patient social network for input on hemophilia trial design

Fierce Pharma

clinical trials

Flag link:

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

Endpoints

Flag link:

Pages